| abstract |
In the present specification, a method for treating a subject having cancer, a method for selecting treatment for a subject having cancer, a method for selecting a subject having cancer relative to a treatment not containing a Trk inhibitor, and a subject having cancer are Trk. How to determine the likelihood of having a positive response to treatment with an inhibitor, how to predict the effectiveness of a Trk inhibitor in a subject with cancer, and how to determine the risk of developing a Trk inhibitor resistant cancer in a subject The method and the presence of a Trk inhibitor resistant cancer in the subject is determined based on detecting cells having at least one of point mutations in NTRK1 and / or NTRK2 and / or NTRK3 in a sample from the subject Provide a method. |